Compounding Pharmacies Market Size Projected to Reach $22.06 billion by 2034 | 5.7%

According to Straits Research, the compounding pharmacies market, valued at $13.39 billion in 2025, is expected to grow from $14.16 billion in 2026 to $22.06 billion by 2034, at a CAGR of 5.7%.

Compounding is the method of combinations and preparations of personalized medicines. These medicines are prepared based on the prescription of the physician, where the individual ingredients are combined according to the dosage form and strength of the prescribed dose. The certified pharmacists are allowed to personalize the medicine for the patient to satisfy their specific needs, such as strengths, dosage forms, flavors, and exclusion of ingredients for which the patient is allergic or sensitive. Although compounded drugs are not approved by the FDA, meaning that the FDA will not check the safety and effectiveness of such drugs. This responsibility lies with the state pharmacy boards, which verify that the state-licensed pharmacies manufacture compound drugs comply with the FDCA section 503A standards.

A compound medication is formulated to meet the needs of a patient. Compounding from common drugs may be used to create custom strengths or dosages. The combination of different ingredients can produce unique treatments that otherwise are not possible with conventional medications. Pharmacists who treat compound pharmaceutical goods represent a niche market and will attract more patients to meet specific needs.

Key Takeaways

• The global compounding pharmacy market is on the rise with a value to the tune of USD 9876.5 million in 2019, firmly backed by several trends such as increasing adoption of personalized medicines and the alarming shortage and recall of drug products from the market.
• The nutritional supplement segment is expected to gain significant market share favored by growing demand for compounded nutritional supplements from rising geriatrics population suffering from obesity and other lifestyle-related disorders.
• North America is estimated to hold a decent share in the global compounding pharmacy market with its significant market contribution coming from the U.S., led by its growing adoption in compounded hormonal therapies by women suffering from menopause-related disorders and with supportive government regulations such as 503A and 503B.
• Prominent market players operating in the compounding pharmacy market are Fresenius Kabi, Fagron, Wedgewood Pharmacy, Lorraine’s Pharmacy, Cantrell Drug Company, Triangle Compounding Pharmacy, Village Compounding Pharmacy, Olympia Pharmacy, and others.
• Fagron strengthened its strategic position in the U.S. market by acquiring Humco in April 2018, a developer of patented vehicles used in compounding pharmacies, and by acquiring JCB laboratories in 2015, one of the high-quality sterile compounding pharmacy in the U.S.

Market Segments

Compounding Pharmacy Market Segmentation

By Dosage forms

• Solid oral preparations
• Liquid preparations
• Topical
• Ophthalmic
• Nasal
• Others

By Therapeutic area

• Hormone Replacement
• Pain Management
• Dermatology applications
• Specialty drugs
• Nutritional supplements
• Others

By Compounding type

• Pharmaceutical ingredient alteration (PIA),
• Pharmaceutical application alteration (PAA),
• Currently unavailable pharmaceutical manufacturing (CUPM)
• Pharmaceutical dosage alteration (PDA)
• Specialized animal pharmaceutical manufacturing (SAPM)

By End-Users

• Adult
• Pediatric
• Geriatric
• Veterinary